133 related articles for article (PubMed ID: 38108830)
21. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.
Talbot JN; Gutman F; Fartoux L; Grange JD; Ganne N; Kerrou K; Grahek D; Montravers F; Poupon R; Rosmorduc O
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1285-9. PubMed ID: 16802155
[TBL] [Abstract][Full Text] [Related]
22. Combined early dynamic
Zhang Y; Dong Y; Yu W; Chen S; Yu H; Li B; Shi H
Abdom Radiol (NY); 2023 Oct; 48(10):3127-3134. PubMed ID: 37439840
[TBL] [Abstract][Full Text] [Related]
23. Change in standardized uptake values in delayed 18F-FDG positron emission tomography images in hepatocellular carcinoma.
Oksuzoglu K; Ones T; Ozguven S; Inanir S; Turoglu HT; Bozkurtlar E; Celikel CA; Erdil TY
Medicine (Baltimore); 2018 Oct; 97(42):e12817. PubMed ID: 30334977
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
25. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma.
Lee JW; Paeng JC; Kang KW; Kwon HW; Suh KS; Chung JK; Lee MC; Lee DS
J Nucl Med; 2009 May; 50(5):682-7. PubMed ID: 19372474
[TBL] [Abstract][Full Text] [Related]
26. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
Ho CL; Chen S; Yeung DW; Cheng TK
J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
[TBL] [Abstract][Full Text] [Related]
27. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
28. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients.
Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ
Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911
[TBL] [Abstract][Full Text] [Related]
29. Role of ¹⁸F-FDG PET CT as an independent prognostic indicator in patients with hepatocellular carcinoma.
Pant V; Sen IB; Soin AS
Nucl Med Commun; 2013 Aug; 34(8):749-57. PubMed ID: 23689586
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
[TBL] [Abstract][Full Text] [Related]
31. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy.
Kim JW; Seong J; Yun M; Lee IJ; Yoon HI; Cho HJ; Han KH
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1172-8. PubMed ID: 21570203
[TBL] [Abstract][Full Text] [Related]
32. [
Zhang J; He Q; Jiang S; Li M; Xue H; Zhang D; Li S; Peng H; Liang J; Liu Z; Rao S; Wang J; Zhang R; Zhang L
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):937-950. PubMed ID: 36346437
[TBL] [Abstract][Full Text] [Related]
33. Assessment of [(18)F]-fluoroacetate PET/CT as a tumor-imaging modality: preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor.
Takemoto K; Hatano E; Nishii R; Kagawa S; Kishibe Y; Takahashi M; Yamauchi H; Matsumura K; Zaima M; Toriguchi K; Tanabe K; Kitamura K; Seo S; Taura K; Endo K; Uemoto S; Higashi T
Ann Nucl Med; 2014 May; 28(4):371-80. PubMed ID: 24599824
[TBL] [Abstract][Full Text] [Related]
34. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
35. [Malignant tumor with false negative 18F-FDG PET image].
Dong MJ; Lin XT; Zhao J; Guan YH; Zuo CT; Chen X; Dai JZ; Jiang BD
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):713-7. PubMed ID: 17274383
[TBL] [Abstract][Full Text] [Related]
36. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization.
Park S; Kim TS; Kang SH; Kim HB; Park JW; Kim SK
Medicine (Baltimore); 2018 Sep; 97(37):e12311. PubMed ID: 30212970
[TBL] [Abstract][Full Text] [Related]
37. Relationships between oxygen and glucose metabolism in human liver tumours: positron emission tomography using (15)O and (18)F-deoxyglucose.
Fukuda K; Taniguchi H; Koh T; Kunishima S; Yamagishi H
Nucl Med Commun; 2004 Jun; 25(6):577-83. PubMed ID: 15167517
[TBL] [Abstract][Full Text] [Related]
38. The Role of 18F-FDG PET/MRI in the Assessment of Primary Intrahepatic Neoplasms.
Çelebi F; Yaghouti K; Cindil E; Dogusoy GB; Tokat Y; Balcı C
Acad Radiol; 2021 Feb; 28(2):189-198. PubMed ID: 32111468
[TBL] [Abstract][Full Text] [Related]
39. Early diagnosis of recurrent hepatocellular carcinoma with 18F-FDG PET after radiofrequency ablation therapy.
Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Iida Y; Higuchi T; Hanaoka H; Miyakubo M; Takano A; Ishikita T; Endo K
Oncol Rep; 2007 Dec; 18(6):1469-73. PubMed ID: 17982632
[TBL] [Abstract][Full Text] [Related]
40. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
Baek S; Mueller A; Lim YS; Lee HC; Lee YJ; Gong G; Kim JS; Ryu JS; Oh SJ; Lee SJ; Bacher-Stier C; Fels L; Koglin N; Schatz CA; Dinkelborg LM; Moon DH
J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
